Feasibility of the Memory and Attention Adaptation-Training Geriatrics Intervention in Older Cancer Survivors With Mild Cognitive Impairment

NCT05258058 | Completed Results DMC

• 2 other identifiers: UCCS19102- Part 2K76AG064394-03S1
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training-Geriatrics (MAAT-G) is a cognitive behavioral therapy-based intervention tailored specifically for older adults and the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment (MCI) is being evaluated.

Conditions

Cognitive Dysfunction

Keywords

cancer-related cognitive difficulties; mild cognitive impairment

Outcome Measures

Primary Outcomes (2)

• MAAT-G Feasibility Completion Rate

  Evaluate the feasibility of MAAT-G in older cancer survivors with mild cognitive impairment by determining study completion rate of this population.

  10 Weeks

• MAAT-G Intervention Adherence Rate

  Evaluate the feasibility of MAAT-G in older cancer survivors with mild cognitive impairment by determining the study intervention adherence rate of this population (proportion of MAAT-G workshops completed).

  10 Weeks

Secondary Outcomes (3)

• Proportion of Patients Who Described at Least One MAAT-G Skill

  10 Weeks

• Change in Cognitive Function (Pre-Post Changes Functional Assessment of Cancer Therapy-Cognition [FACT-Cog])

  10 Weeks

• Mean Usability

  10 Weeks

Study Arms (1)

MAAT-G Intervention

EXPERIMENTAL

MAAT-G Workshops \& participant workbook use (8 workshops)

Behavioral: Memory and Adaptation Training-Geriatrics

Interventions

Memory and Adaptation Training-Geriatrics BEHAVIORAL

MAAT-G is a cognitive behavioral therapy-based intervention comprised of 10 workshop sessions as well as a participant workbook. The workshop sessions are delivered one on one by a health professional via videoconferencing technology.

Also known as: MAAT-G

MAAT-G Intervention

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Be age 65 or older
• Able to provide informed consent. All patients will be assessed using the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC)56 - a score \>14.5 will define ability to independently provide informed consent. For patients scoring \<14.5, or if investigators have additional concerns, we will require that their health care proxy participate in the consenting process and sign an informed consent and patients will required to provide assent.
• Able to read and understand English
• Have a prior diagnosis of cancer and completed curative intent chemotherapy. Patients are permitted to be receiving maintenance therapy (e.g. endocrine therapy) in the adjuvant setting.
• Have a clinical diagnosis of MCI, a score \<26 on the Montreal Cognitive Assessment (MOCA), or a score \<18 on the Montreal Cognitive Assessment-BLIND (MOCA-BLIND). If the patient had a MOCA evaluation completed as a part of routine clinical care in the preceding 3 months prior to consent date, this may be used for eligibility purposes.
• Be independent in Activities of Daily Living (ADL)

Sponsors & Collaborators

• Allison Magnuson: lead
• National Institute on Aging (NIA): collaborator

Study Sites (1)

University of Rochester

Rochester, New York, 14642, United States

Location

MeSH Terms

Conditions

Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Results Point of Contact

• Title: Dr. Allison Magnuson
• Organization: University of Rochester

allison_magnuson@urmc.rochester.edu

585-602-5085

Study Officials

• Allison Magnuson

  Univ. of Rochester Wilmot Cancer Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor - Department of Medicine , Hematology/Oncology (SMD)

Study Record Dates

• First Submitted: February 17, 2022
• First Posted: February 28, 2022
• Study Start: December 10, 2021
• Primary Completion: July 20, 2023
• Study Completion: July 26, 2023
• Last Updated: July 10, 2024
• Results First Posted: July 10, 2024

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will share

Locations

US (1)